# Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

> **NCT05805098** · PHASE2,PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Homoharringtonine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT05805098
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05805098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05805098, "Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05805098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*